Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

被引：1
作者：
Chen, Ruochan [1 ,2 ]
Pei, Siya [1 ,2 ]
Chen, Yayu [1 ,2 ]
Tan, Linxia [1 ,2 ]
Xue, Ying [3 ,4 ,5 ]
Liu, Shao [3 ,4 ,5 ]
Huang, Yan [1 ,2 ]
Fan, Xuegong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Hunan Key Lab Viral Hepatitis, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Peoples R China
[4] Hunan Inst Pharm Pract & Clin Res, Changsha, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Inst Rational & Safe Medicat Pract, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China
来源：
FRONTIERS IN MEDICINE | 2021年 / 8卷
关键词：
tenofovir alafenamide; suboptimal response; HBeAg-positive chronic hepatitis B; monotherapy; case report; DRUG-RESISTANT HBV; DISOPROXIL FUMARATE; ENTECAVIR; ADEFOVIR; THERAPY; MONOTHERAPY; INFECTION; SAFETY;
D O I：
10.3389/fmed.2021.701061
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.
引用
收藏
页数：6
相关论文
共 28 条
  • [1] Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340
    Babusis, Darius
    Phan, Truc K.
    Lee, William A.
    Watkins, William J.
    Ray, Adrian S.
    [J]. MOLECULAR PHARMACEUTICS, 2013, 10 (02) : 459 - 466
  • [2] Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Baldick, Carl J.
    Tenney, Daniel J.
    Mazzucco, Charles E.
    Eggers, Betsy J.
    Rose, Ronald E.
    Pokornowski, Kevin A.
    Yu, Cheng F.
    Colonno, Richard J.
    [J]. HEPATOLOGY, 2008, 47 (05) : 1473 - 1482
  • [3] Buti M, 2016, LANCET GASTROENTEROL, V1, P90, DOI [10.1016/S2468-1253(16)30020-6, 10.1016/S2468-1253(16)30107-8]
  • [4] Cathcart AL, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01064-18, 10.1128/aac.01064-18]
  • [5] Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
    Chan, Henry L. Y.
    Fung, Scott
    Seto, Wai Kay
    Chuang, Wan-Long
    Chen, Chi-Yi
    Kim, Hyungjoon
    Hui, Aric Josun
    Janssen, Harry L. A.
    Chowdhury, Abhijit
    Tsang, Tak Yin Owen
    Mehta, Rajiv
    Gane, Edward
    Flaherty, John F.
    Massetto, Benedetta
    Gaggar, Anuj
    Kitrinos, Kathryn M.
    Lin, Lanjia
    Subramanian, G. Mani
    McHutchison, John G.
    Lim, Young-Suk
    Acharya, Subrat K.
    Agarwal, Kosh
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03): : 185 - 195
  • [6] Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naive chronic hepatitis B: A case report and review of the literature
    Cho, Woo Hee
    Lee, Hyun Jae
    Bang, Ki Bae
    Kim, Seok Bae
    Song, Il Han
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (17) : 1919 - 1924
  • [7] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [8] Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide
    Fong, Tse-Ling
    Lee, Brian T.
    Tien, Andy
    Chang, Mimi
    Lim, Carolina
    Ahn, Alden
    Bae, Ho S.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2019, 26 (05) : 561 - 567
  • [9] Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
    Heathcote, E. Jenny
    Marcellin, Patrick
    Buti, Maria
    Gane, Edward
    De Man, Robert A.
    Krastev, Zahary
    Germanidis, George
    Lee, Samuel S.
    Flisiak, Robert
    Kaita, Kelly
    Manns, Michael
    Kotzev, Iskren
    Tchernev, Konstantin
    Buggisch, Peter
    Weilert, Frank
    Kurdas, Oya Ovunc
    Shiffman, Mitchell L.
    Trinh, Huy
    Gurel, Selim
    Snow-Lampart, Andrea
    Borroto-Esoda, Katyna
    Mondou, Elsa
    Anderson, Jane
    Sorbel, Jeff
    Rousseau, Franck
    [J]. GASTROENTEROLOGY, 2011, 140 (01) : 132 - 143
  • [10] Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis
    Huang, Ze-Bing
    Zhao, Shu-Shan
    Huang, Yan
    Dai, Xia-Hong
    Zhou, Rong-Rong
    Yi, Pan-Pan
    Chen, Ruo-Chan
    Li, Wen-Ting
    Zhang, Bao-Xin
    Li, Ning
    Fan, Xue-Gong
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (12) : 1997 - 2006
123